

Notification of Medicare Part D Negative Formulary Change(s)

To: State Pharmaceutical Assistance Programs, Entities Providing Other Prescription Drug Coverage, Authorized Prescribers, Network Pharmacies, and Pharmacists

From: Prime Therapeutics LLC

Subject: December 2022 Notification of Medicare Part D Negative Formulary Change(s)

Prime Therapeutics LLC (Prime) manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. Prime supports several Medicare Part D Plan Sponsors (Part D Sponsors) and serves over 1 million Medicare beneficiaries. During the year, the Centers for Medicare & Medicaid Services (CMS) may approve changes including the removal of drugs or the addition of restrictions or limits to certain drugs, to the list of Medicare Part D covered drugs. When CMS approves a change, Prime provides at least 30 days notice to both the Part D Sponsors' impacted members and other individuals and organizations that may work with these members, before the negative formulary change(s) take effect. When the change is because the Food and Drug Administration deems a Part D drug to be unsafe, the manufacturer removes the drug from market, or a brand drug is replaced with its generic or is tier raised, Prime will provide retrospective notice as soon as possible. In accordance with Medicare Part D requirements and CMS' approval, Prime is providing notification of the following Medicare Part D negative formulary change(s):

| Drug | Type of Change | Reason for Change | Effective Date of Change | Formulary/Formularies Impacted |
|------------------------------------|--------------------------------|-----------------------|--------------------------|---|
| DALIRESP tabs, 250 mcg, 500 mcg | Will be removed from drug list | Generic now available | 11/04/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| GILENYA caps, 0.5 mg | Will be removed from drug list | Generic now available | 11/15/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (LCE, HCE, DSB, & MAPD) Client Specific Formularies (Asuris, Capital Blue Cross, HCSC Semicustom, HCSC DSB, Horizon, Regence) |



The Part D Sponsors' members who are impacted by the change(s) will receive notification on their monthly Explanation of Benefits (EoB). Since you may interact with the Part D Sponsors' members, Prime is providing you this notice prior to the date the change becomes effective so that you may take any appropriate action as you work with the Part D Sponsors' members, which may include considering alternative drugs that are covered by the plan or asking the plan for an exception.

For more information about how the change(s) may affect cost-sharing, such as copayments or coinsurance, or for more information about asking the plan for an exception, please visit MyPrime.com. (Note: There is no access to Regence or Asuris on MyPrime.com. Please visit Regence.com or Asuris.com for additional information on those health plans).

Prior Negative Formulary Changes in 2022

| Drug | Type of Change | Reason for Change | Effective Date of Change | Formulary/Formularies Impacted |
|---|--------------------------------|-----------------------|--------------------------|--|
| AFINITOR DISPERZ tabs for oral susp, 2 mg, 3 mg, 5 mg | Will be removed from drug list | Generic now available | 01/01/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| AFINITOR tabs, 10 mg | Will be removed from drug list | Generic now available | 01/01/2022 | Client Specific Formularies (Horizon, Asuris, Regence) |
| ARRANON inj, 5 mg/mL | Will be removed from drug list | Generic now available | 01/01/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |



| Drug | Type of Change | Reason for Change | Effective Date of Change | Formulary/Formularies Impacted |
|---|--------------------------------|-----------------------|--------------------------|--|
| BYSTOLIC tabs, 2.5 mg, 5 mg, 10 mg, 20 mg | Will be removed from drug list | Generic now available | 01/01/2022 | Ideal & Value Plus Formularies Center of Excellence Formularies (LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC Semi-Custom & HCSC DSB, Horizon, Regence) |
| CARBAGLU tabs, 200 mg | Will be removed from drug list | Generic now available | 01/01/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| CHANTIX continuing month pack tabs, 1 mg | Will be removed from drug list | Generic now available | 01/01/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| CHANTIX tabs, 0.5 mg, 1 mg | Will be removed from drug list | Generic now available | 01/01/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| DUREZOL ophth emulsion, 0.05% | Will be removed from drug list | Generic now available | 01/01/2022 | Ideal Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |



| | Т | | | THESABELITI |
|--------------------------------------|--------------------------------|-----------------------|--------------------------|--|
| Drug | Type of Change | Reason for Change | Effective Date of Change | Formulary/Formularies Impacted |
| ZORTRESS tabs, 1 mg | Will be removed from drug list | Generic now available | 01/01/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Capital Blue Cross, HCSC, Horizon) |
| NARCAN nasal spray, 4 mg/0.1 mL | Will be removed from drug list | Generic now available | 01/31/2022 | Client Specific Formularies (Alignment, Horizon) |
| ISTODAX (OVERFILL) for IV inj, 10 mg | Will be removed from drug list | Generic now available | 02/04/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Capital Blue Cross, HCSC, Horizon) |
| CYSTADANE powder for oral solution | Will be removed from drug list | Generic now available | 02/22/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| SELZENTRY tab, 150 mg, 300 mg | Will be removed from drug list | Generic now available | 02/22/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |



| | | | ECC .: 5 : | THESABELTI |
|---|--------------------------------|------------------------------|--------------------------|--|
| Drug | Type of Change | Reason for Change | Effective Date of Change | Formulary/Formularies Impacted |
| AMBISOME iv for susp, 50 mg | Will be removed from drug list | Generic now available | 02/28/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| VIMPAT tab, 50 mg, 100 mg, 150 mg, 200 mg | Will be removed from drug list | Generic now available | 03/30/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| RUZURGI tab, 10 mg | Will be removed from drug list | Discontinued by manufacturer | 05/24/2022 | Complete Formulary |
| VIMPAT iv inj, 200 mg/20mL (10 mg/mL) | Will be removed from drug list | Generic now available | 04/26/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| COMBIGAN ophth soln, 0.2-0.5% | Will be removed from drug list | Generic now available | 04/28/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |



| Drug | Type of Change | Reason for Change | Effective Date of Change | Formulary/Formularies Impacted |
|------------------------------------|--------------------------------|---|--------------------------|--|
| ESBRIET tabs, 267 mg, 801 mg | Will be removed from drug list | Generic now available | 05/26/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| ORAVIG tab, 50 mg | Will be removed from drug list | No longer covered by Medicare Part D | 06/01/2022 | Complete Formulary |
| ZUPLENZ film, 4 mg, 8 mg | Will be removed from drug list | No longer covered by Medicare Part D | 06/01/2022 | Complete Formulary |
| VIMPAT soln, 10 mg/mL | Will be removed from drug list | Generic now available | 06/08/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| VIMPAT soln, 10 mg/mL | Will increase in tier | Generic now available | 06/08/2022 | Expanded, Complete Formulary |
| PENTASA cap, 500 mg | Will be removed from drug list | Generic now available | 06/09/2022 | Ideal Formularies Center of Excellence Formularies (HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Capital Blue Cross, HCSC Semi-Custom) |
| ALIMTA for iv soln, 100 mg, 500 mg | Will be removed from drug list | Generic now available | 06/22/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |



| Drug | Type of Change | Reason for Change | Effective Date of Change | Formulary/Formularies Impacted |
|-------------------------------------|--------------------------------|------------------------------|--------------------------|--|
| VIIBRYD tab, 10 mg, 20 mg, 40 mg | Will be removed from drug list | Generic now available | 06/23/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| TARGRETIN gel, 1% | Will be removed from drug list | Generic now available | 06/28/2022 | Ideal, Value, Value Plus & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| UKONIQ tab, 200 mg | Will be removed from drug list | Discontinued by manufacturer | 08/23/2022 | Ideal, Value, Value Plus, Expanded, Complete & Essential Formularies Center of Excellence Formularies (Basic, LCE, HCE, DSB, & MAPD) Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence) |
| TOVIAZ tab, 4 mg | Will be removed from drug list | Generic now available | 08/17/2022 | Ideal, Value Plus, Center of Excellence Formularies (LCE) Client Specific Formularies (Capital Blue Cross) |
| TOVIAZ tab, 4 mg | Will increase in tier | Generic now available | 08/17/2022 | Complete and Expanded Formularies |
| TOVIAZ tab, 8 mg | Will be removed from drug list | Generic now available | 08/17/2022 | Ideal, Value Plus, Center of Excellence Formularies (LCE) Client Specific Formularies (Capital Blue Cross) |
| TOVIAZ tab, 8 mg | Will increase in tier | Generic now available | 08/17/2022 | Complete and Expanded Formularies |
| VASCEPA caps, 0.5 gm | Will be removed from drug list | Generic now available | 10/06/2022 | Client Specific Formulary (Horizon) |



| Drug | Type of Change | Reason for Change | Effective Date of Change | Formulary/Formularies Impacted |
|--------------------------|--------------------------------|-----------------------|--------------------------|--|
| TAZORAC gel, 0.05%, 0.1% | Will be removed from drug list | Generic now available | 10/07/2022 | Client Specific Formulary (Capital Blue Cross) |